KACIE BLACKWELL: Open Payments
NPI 1427400217 · HAMMOND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$712 in 36 payments from 17 companies in 2025. Trend: 2023 $72 · 2024 $985 · 2025 $712
Food & beverage: $712
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 7 | $143 |
| Lilly USA, LLC | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Boston Scientific Corporation | 1 | $53 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| AstraZeneca Pharmaceuticals LP | 3 | $48 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $39 |
| Amgen Inc. | 2 | $38 |
| Antares Pharma, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
Products named: TRELEGY ELLIPTA, TRINTELLIX, MOUNJARO, AMS 700, VOQUEZNA, BREZTRI, SHINGRIX, XIFAXAN.
Industry payments across LA — which companies pay providers there.
